Sanofi and Regeneron Announce New Results from Six Phase 3 Trials Showing that Alirocumab Significantly Reduced LDL Cholesterol

PARIS AND TARRYTOWN N.Y. Nov. 19 2014 PRNewswire &160;Sanofi and Regeneron Pharmaceuticals Inc. NASDAQ REGN today announced new detailed positive results from six Phase 3 ODYSSEY trials that showed alirocumab significantly reduced lowdensity lipoprotei...